NewAmsterdam Pharma Stock Rises as Fresh Filing Puts Its $4.3 Billion Drug Bet in Focus
NewAmsterdam Pharma Company N.V. shares head into Thursday’s U.S. session with a fresh insider filing in the tape and the stock still priced around the next tests for obicetrapib, its late-stage cholesterol drug. NAMS last traded at $36.56, up about 1.3% from its previous close, with a market value near $4.27 billion. That move stood out against a quiet broader tape. A Reuters market-data snapshot showed the S&P 500 up 0.02% and the Nasdaq Composite up 0.07%, leaving the company’s shares moving more on its own news flow than on index strength.